These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 3290356)

  • 1. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical nitroglycerin ointment in Raynaud's phenomenon.
    Fischer M; Reinhold B; Falck H; Török M; Alexander K
    Z Kardiol; 1985 May; 74(5):298-302. PubMed ID: 3925656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 12. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
    Wise RA; Malamet R; Wigley FM
    J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketanserin and capillary flow in Raynaud's phenomenon.
    Tooke JE; Williams SA; Rawlinson DW; Black C
    Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
    Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
    J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
    Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
    Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
    Marasini B; Bassani C
    Br J Clin Pharmacol; 1990 Dec; 30(6):847-51. PubMed ID: 2288831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.